Mycenax (4726) is pleased to share that our strategic partnership with Cytiva has been featured by GeneOnline.
As biopharma manufacturing transitions from traditional experience-based approaches to data-driven process development, Mycenax is advancing its capabilities by integrating Cytiva’s GoSilico™ digital twin platform and Single-Use Systems (SUS). This collaboration enhances our downstream bioprocessing efficiency, flexibility, and scalability to support global biopharma development.
Read the full report on GeneOnline to learn more about how Mycenax and Cytiva are advancing the biomanufacturing ecosystem together.
Cytiva Partners with Mycenax Biotech to Build AI-Driven and Future-Ready Downstream Bioprocessing - GeneOnline News
Jeff Wang, Business Head of Cytiva Taiwan, and Dr. Pei-Jiun Chen, CEO and President of Mycenax, marked the partnership with a symbolic sand-pouring ceremony. Demonstrating long-standing trust and mutual dedication under the theme "Advancing Together," both companies are committed to driving innovation and empowering the global expansion of Taiwan's biopharma industry.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
Mycenax (4726) is pleased to share that our strategic partnership with Cytiva has been featured by GeneOnline.
As biopharma manufacturing transitions from traditional experience-based approaches to data-driven process development, Mycenax is advancing its capabilities by integrating Cytiva’s GoSilico™ digital twin platform and Single-Use Systems (SUS). This collaboration enhances our downstream bioprocessing efficiency, flexibility, and scalability to support global biopharma development.
Read the full report on GeneOnline to learn more about how Mycenax and Cytiva are advancing the biomanufacturing ecosystem together.
Cytiva Partners with Mycenax Biotech to Build AI-Driven and Future-Ready Downstream Bioprocessing - GeneOnline News
Jeff Wang, Business Head of Cytiva Taiwan, and Dr. Pei-Jiun Chen, CEO and President of Mycenax, marked the partnership with a symbolic sand-pouring ceremony. Demonstrating long-standing trust and mutual dedication under the theme "Advancing Together," both companies are committed to driving innovation and empowering the global expansion of Taiwan's biopharma industry.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
